Impairment of renal function in the breast cancer patients with bone metastases treated with zoledronic acid

被引：0
|
作者：
Ito, Tokiko [1 ]
Ono, Mayu [1 ]
Oba, Takaaki [1 ]
Hanamura, Toru [1 ]
Kanai, Toshiharu [1 ]
Maeno, Kazuma [1 ]
Hiraguri, Manabu [3 ]
Shingu, Kiyoshi [2 ]
Kaneko, Gengo [3 ]
Ito, Ken-ichi [1 ]
机构：
[1] Shinshu Univ, Sch Med, Div Breast & Endocrine Surg, Matsumoto, Nagano, Japan
[2] Iida Municipal Hosp, Div Breast & Endocrine Surg, Nagano, Japan
[3] Iida Municipal Hosp, Div Surg, Nagano, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O3-14-3
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] IMPAIRMENT OF RENAL FUNCTION IN THE BREAST CANCER PATIENTS WITH BONE METASTASES TREATED WITH ZOLEDRONIC ACID
    Ito, T.
    Shingu, K.
    Kaneko, G.
    Ito, K. -I.
    [J]. ANNALS OF ONCOLOGY, 2013, 24
  • [2] The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
    Oh, William K.
    Proctor, Kevin
    Nakabayashi, Mari
    Evan, Carolyn
    Tormey, Lauren K.
    Daskivich, Timothy
    Antras, Lucia
    Smith, Michael
    Neary, Maureen P.
    Duh, Mei Sheng
    [J]. CANCER, 2007, 109 (06) : 1090 - 1096
  • [3] Renal function among cancer patients with bone metastases treated with zoledronic acid in a real world setting
    Nordstrom, B. L.
    Langer, C.
    Hussain, A.
    Barghout, V.
    Modi, D.
    Lacerna, L.
    Gralow, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Zoledronic acid for the prevention of bone metastases in patients with breast cancer
    Coleman, R.
    Gralow, J.
    Bell, R.
    Lipton, A.
    [J]. EJC SUPPLEMENTS, 2004, 2 (03): : 74 - 75
  • [5] NTX and VEGF in cancer patients with bone metastases treated with zoledronic acid
    Mercatali, L.
    Ibrahim, T.
    Sacanna, E.
    Ricci, R.
    Scarpi, E.
    Fabbri, F.
    Serra, P.
    Tison, C.
    Amadori, D.
    [J]. EJC SUPPLEMENTS, 2010, 8 (05): : 23 - 23
  • [6] Breast cancer bone metastases: denosumab or zoledronic acid?
    Gabri van der Pluijm
    [J]. Nature Reviews Endocrinology, 2011, 7 : 134 - 135
  • [7] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Murat Dincer
    Kadri Altundag
    Hakan Harputluoglu
    Sercan Aksoy
    Mustafa Cengiz
    Ibrahim Gullu
    [J]. Medical Oncology, 2008, 25 : 356 - 359
  • [8] CANCER Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm, Gabri
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (03) : 134 - 135
  • [9] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Dincer, Murat
    Altundag, Kadri
    Harputluoglu, Hakan
    Aksoy, Sercan
    Cengiz, Mustafa
    Gullu, Ibrahim
    [J]. MEDICAL ONCOLOGY, 2008, 25 (03) : 356 - 359
  • [10] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Altundag, M. K.
    Dincer, M.
    Harputluoglu, H.
    Aksoy, S.
    Ozisik, Y.
    Guler, N.
    Tekuzman, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345